Who is sponsoring NCT01951482?

NCT01951482 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT01951482?

Interventions in NCT01951482: Pemetrexed/Platinum, Bevacizumab and Pemetrexed/platinum.

What condition does NCT01951482 study?

NCT01951482 studies Non Squamous Non-small Cell Lung Cancer, Brain Metastases, Bevacizumab.

Is NCT01951482 still recruiting?

NCT01951482 is currently completed. Last updated 13 August 2025.

Last reviewed 2025-08-13 · How we verify

NCT01951482

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab+Pemetrexed/Platinum Versus Pemetrexed/Platinum as First-line Therapy in EGFR/ALK Negative Non-squamous Non-small Cell Lung Cancer Patients With Brain Metastases: a Multicenter, Randomized, Controlled, Phase 3 Study

Completed Phase 3 Last updated 13 August 2025

What this trial tests

Phase 3 trial testing Pemetrexed/Platinum in Non Squamous Non-small Cell Lung Cancer in 160 participants. Completed in 1 December 2024.

Timeline

1 January 2016

Primary endpoint
1 December 2023

1 December 2024

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	1 January 2016
Primary completion	1 December 2023
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

Pemetrexed/Platinum — full drug profile →
Bevacizumab and Pemetrexed/platinum — full drug profile →

Conditions studied

Non Squamous Non-small Cell Lung Cancer — all drugs for Non Squamous Non-small Cell Lung Cancer →
Brain Metastases — all drugs for Brain Metastases →
Bevacizumab — all drugs for Bevacizumab →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 80, any sex, with Non Squamous Non-small Cell Lung Cancer or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Compare iPFS(intracranial progression free survival) in two arms
Time frame: 3 Years

Sponsor's own description

This is a multi-center phase 3 randomized controlled study to assess the efficacy of Pemetrexed/platinum with or without Bevacizumab on patients with brain metastasis from non-small cell lung cancer(NSCLC) harboring EGFR/ALK wild type by intracranial PFS(iPFS), also PFS ,ORR, DCR and OS. The safety is evaluated as well.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.
Vacchelli E, Aranda F, Eggermont A, Galon J, et al · · 2014 · cited 54× · PMID 24605265 · DOI 10.4161/onci.27048
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.
Li M, Pan Y, Jiang G, Wang Q, et al · · 2025 · PMID 41270700 · DOI 10.1016/j.esmoop.2025.105908

Verify or expand the search:

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01951482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 13 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01951482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing